Welcome to the Mesothelioma Help Ask-A-Nurse interview session. We re privileged to be talking to a doctor and 2 nurses with mesothelioma experience.
Lisa Hyde-Barrett who has been a thoracic surgery nurse for nearly 25 years and has had the privilege of caring for countless mesothelioma patients over the years, offers key medical information to the readers.
Ellie Erickson has been working in the surgical intensive care unit at Brigham and Woman s Hospital since 1985. Before then she worked in the cardiothoracic ICU and the ICU float pool. She earned her diploma in nursing from the Mount Auburn Hospital School of Nursing in 1978 and earned her BSN from Worcester State College in 1982.
Dr. DaSilva [inaudible 00:01:05] at Layola University Medical Center and Professor of Surgery at the Stritch School of Medicine in Chicago. He is the co-director of the Lung Cancer Program and the Director of the International Mid-Western Mesothelioma Program, Cardinal Bernardin Cancer Center.
So we
Brachytherapy may proceed safely in cervical cancer patients following uterine perforation
A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells, may continue safely, potentially without delay or antibiotics, in cervical cancer patients following uterine perforation.
According to the World Health Organization, cervical cancer is the fourth most common cancer in women. Treatment for cervical cancer often involves brachytherapy combined with daily radiation therapy.
Brachytherapy delivers radiation directly to cancer cells through a tube placed within the uterus.
At times this tube can pierce the uterus and lead to a perforation. Many clinicians will not proceed with the treatment when a perforation occurs. This can lead to delays in therapy that may increase the recurrence risk and potentially lead to worse survival rates.
A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells, may continue safely, potentially without delay or antibiotics, in cervical cancer patients following uterine perforation.